Remplir Shows Excellent Early Prostatectomy Results
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Orthocell Ltd has announced excellent early clinical outcomes from its Remplir product used in nerve-sparing prostate cancer surgeries, highlighting significant functional recovery in patients with advanced prostate cancer. The initial case series showed that a majority of patients experienced encouraging urinary continence and erectile function outcomes, with no complications reported during surgery or follow-up. The company plans to gather further clinical evidence to support a U.S. launch, as Remplir is already approved in multiple jurisdictions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Orthocell
- Letter to Shareholders, Notice of AGM & Proxy Form
- Change of Auditor
- Orthocell Achieves First Remplir Sales in Thailand
- Cleansing Notice
- Application for quotation of securities - OCC
Later from Orthocell
- Orthocell Investor Webinar Details
- Quarterly Activity Report & Appendix 4C
- Q1 FY27 OCC Investor Presentation
- Strongest U.S. Remplir Sales Month Since Launch
- Marine Biomedical Achieves FDA Clearance
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell